In re Androgel Products Liability Litigation

24 F. Supp. 3d 1378, 2014 U.S. Dist. LEXIS 77052, 2014 WL 2547824

• Court: United States Judicial Panel on Multidistrict Litigation
• Decided: June 6, 2014
• Docket: MDL No. 2545
• Status: Published

Opinion

TRANSFER ORDER

JOHH G. HEYBURN II, Chairman.

Before the Panel:

* Pursuant to 28 U.S.C. § 1407, plaintiffs in 15 Northern District of Illinois actions and plaintiffs in an action (Barrios) pending in the Eastern District of Louisiana move, separately, to centralize this litigation involving injuries arising from the use of testosterone replacement therapies in, respectively, the Northern District of Illinois or the Eastern District of Louisiana. The Eastern District of Louisiana movants alternatively suggest centralization in the Eastern District of Pennsylvania. This litigation currently consists of 45 actions pending in four districts, as listed on Schedule A.

1

At oral argument, plaintiffs asserted that all responding plaintiffs now support centralization of all cases involving injuries arising from the use of testosterone replacement therapies, regardless of manufacturer. Plaintiffs have variously suggested the following districts be selected as the transferee district: the Central District of California, the Eastern District of Louisiana, the Southern and Northern Districts of Illinois, the Eastern District of Pennsylvania, the District of New Jersey and the Eastern District of New York.

Defendants’ positions on the motions for centralization vary significantly. Defendants AbbVie Inc. and Abbott Laboratories Inc. (collectively Abbbot); Eli Lilly and Co. and Lilly USA LLC; and Endo Pharmaceuticals, support establishing an all-testosterone replacement therapy MDL in the Northern District of Illinois. Defendant Actavis, Inc. opposes creation of an all-testosterone therapy MDL but does not oppose transferring cases in which plaintiff took AndroGel and one of its testosterone products, the AndroDerm patch, to an MDL involving Abbott’s AndroGel product. ■ Defendant Auxilium Pharmaceuticals, Inc., opposes creation of an all-testosterone replacement therapy MDL but does not oppose the creation of an Andro-Gel-only MDL, and argues that any MDL created should be located in N.D. Illinois. Defendants Pfizer, Inc. and Pharmacia & Upjohn Co. suggest creation of an MDL involving testosterone replacement gels only, opposes inclusion of cases against them in any MDL and suggest Section 1407 separation and remand of non-gel testosterone replacement therapy claims.

On the basis of the papers filed and hearing session held, we find that these actions involve common questions of fact, and that centralization of all actions in the Northern District of Illinois will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. On January 31, 2014, the U.S. Food and Drug Administration announced that it was “investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products.” Plaintiffs filed the actions now before us in the wake of this announcement. All actions involve plaintiffs (or their survivors) who used one or more testosterone replacement therapies and contend that their (or their decedent’s) use of the drugs caused their injuries, which include heart attack, stroke, deep vein thrombosis, and pulmonary embolism. All testosterone replacement therapy actions will share factual questions regarding general causation and the background science regarding the role of testosterone in the aging body (possibly including examination of the recent studies that prompted the FDA investigation), as well as involve common regulatory issues in light of the FDA’s announcement and subsequent actions, if any.

We are typically hesitant to centralize litigation on an industry-wide basis. In these circumstances, however, we think it is the best solution. Plaintiffs suggest that related cases will number in the thousands. Significantly, in the actions and potential tag-along actions already filed, a number of plaintiffs used more than one testosterone replacement therapy. The other approaches proposed by the parties — centralizing only AndroGel cases (and perhaps transferring “combination cases”), separating and remanding claims against certain manufacturers, or transferring only claims related to testosterone replacement gels — could prove too procedurally complicated, might result in a de facto industry-wide centralization as cases involving multiple drugs become part of the MDL, or may require successive motions for centralization. All of these alternative proposals likely would delay the resolution of the common core issues in this litigation.

Our decision here is in keeping with our past decisions in similar circumstances. For instance, we recently centralized litigation involving multiple manufacturers involving a class of diabetes drugs. See, e.g., In re: Incretin Mimetics Prods. Liab. Litig., 968 F.Supp.2d 1345 (J.P.M.L.2013) (centralizing actions against competing defendants which manufactured four similar diabetes drugs that allegedly caused pancreatic cancer). Similarly, we also have centralized other hormone replacement therapy on an industry-wide basis. See MDL No. 1507 — In re: Prempro Products Liab. Litig. (originally centralized to include only Wyeth’s hormone replacement therapy products but later expanded to include other Wyeth products and the drugs of other manufacturers). Centralization of claims involving all testosterone replacement therapies will reduce potentially costly expert discovery, facilitate the establishment of a uniform pretrial approach to these cases, reduce the potential for inconsistent rulings on such matters as Daubert rulings, and conserve the resources of the parties, their counsel, and the judiciary.

We are sympathetic to the concerns expressed by defendants against which only a few actions have been filed, particularly their concern that the claims against them may linger in an MDL in which the majority of claims are brought against the Abbott defendants, whose AndroGel product has a substantial market share. We are confident that any issues involving these different products and defendants can be accommodated by the transferee judge in a manner that guarantees the just and efficient resolution of all cases. For instance, the transferee judge may find it advisable to establish separate discovery and motion tracks for the various products. As with any other litigation, the transferee judge retains wide discretion as to how the MDL should be defined, and if, after close scrutiny, the transferee judge determines that remand of any claims or actions involving any particular product is appropriate, procedures are available whereby this may be accomplished with a minimum of delay. See Panel Rule 10.1.

The Northern District of Illinois is an appropriate transferee district for this litigation. This district provides a convenient and accessible forum for actions filed throughout the country regarding products sold nationwide. A significant number of actions are pending in this district, which is also where the Abbott defendants are based. Judge Matthew F. Kennelly, an experienced MDL jurist, is presiding over most of the actions pending in this district and already has taken initial steps to organize this litigation. We are confident that he will steer this litigation on a prudent course.

IT IS THEREFORE ORDERED that pursuant to 28 U.S.C. § 1407, the actions listed in Schedule A are transferred to the Northern District of Illinois and, with the consent of that court, assigned to the Honorable Matthew F. Kennelly for coordinated or consolidated pretrial proceedings.

IT IS FURTHER ORDERED that, in light of this opinion, the MDL caption is changed to In re: Testosterone Replacement Therapy Products Liability Litigation.

SCHEDULE A

MDL No. 2545 — IN RE: ANDROGEL PRODUCTS LIABILITY LITIGATION

District of Colorado

SCHENKEIN v. ABBVIE, INC., ET AL., C.A. No. 1:14-00910

Northern District of Illinois

AURECCHIA V. ABBVIE INC. ET AL., C.A. No. 1:14-00772

MARINO v. ABBVIE, INC., ET AL., C.A. No. 1:14-00777

MYERS v. ABBVIE, INC, ET AL., C.A. No. 1:14-00780

CRIPE v. ABBVIE, INC, ET AL., C.A. No. 1:14-00843

JOHNSON v. ABBVIE, INC., ET AL., C.A. No. 1:14-00877

KELLY, SR. v. ABBVIE, INC., ET AL., C.A. No. 1:14-00879

GIBBY, ET AL. v. ABBVIE, INC., ET AL., C.A. No. 1:14-00917

HARDEE, ET AL. v. ABBVIE, INC., ET AL., C.A. No. 1:14-00918

LAD v. ABBVIE, INC, ET AL., C.A. No. 1:14-01298

BARTHOLIC v. ABBVIE, INC., ET AL., C.A. No. 1:14-01427

O’DONNELL v. ABBVIE, INC., ET AL., C.A. No. 1:14-01428

BLADES, ET AL. v. ABBVIE, INC., ET AL., C.A. No. 1:14-01471

CARPENTER, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01472

HUMPHRIES, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01473

DOBBS v. ABBVIE, INC, ET AL., C.A. No. 1:14-01474

HEADLEY v. ABBVIE, INC, ET AL., C.A. No. 1:14-01475

HUGHES, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01476

JACKSON, ET AL. v. ABBVIE INC., C.A. No. 1:14-01477

GORDON v. ABBVIE, INC, ET AL., C.A. No. 1:14-01478

JONES, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01479

KING, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01480

LEWIS, ET AL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01481

SAYLOR, ETAL. v. ABBVIE, INC, ET AL., C.A. No. 1:14-01482

CATAUDELLA v. ABBVIE, INC., ET AL., C.A. No. 1:14-01483

BAILEY v. ABBVIE, INC, ET AL., C.A. No. 1:14-01663

GORDON v. ABBVIE, INC, ET AL., C.A. No. 1:14-01665

WHITE v. ABBVIE, INC, ET AL., C.A. No. 1:14-01667

MONTGOMERY v. ABBVIE, INC, ET AL., C.A. No. 1:14-01668

ORTIZ v. ABBVIE, INC, ET AL., C.A. No. 1:14-01670

DELEON v. ABBVIE, INC, ET AL., C.A. No. 1:14-01673

DULA v. ABBVIE, INC, ET AL., C.A. No. 1:14-01726

LAROCHE v. ABBVIE, INC., ET AL., C.A. No. 1:14-01826

GEORGE v. ABBVIE, INC, ET AL., C.A. No. 1:14-02085

LUECK v. ABBVIE, INC, ET AL., C.A. No. 1:14-02140

EMMONS v. ABBVIE, INC., ET AL., C.A. No. 1:14-02221

DARBY, ET AL. v. ABBVIE, INC., ET AL., C.A. No. 1:14-02227

KOMRADA V. ABBVIE INC. ET AL., C.A. No. 1:14-02429

Eastern District of Louisiana

PEULER, ET AL. V. AUXILIUM PHARMACEUTICALS, INC., C.A. No. 2:14-00658

LOCOCO, ET AL V. ABBVIE, INC, ET AL., C.A. No. 2:14-00774

BARRIOS, ET AL. V ABBVIE, INC., ET AL., C.A. No. 2:14-00889

Eastern District of Pennsylvania

TEJEDA v. ABBVIE, INC, ET AL., C.A. No. 2:14-00946

HUSTED V. ABBVIE INC, ET AL., C.A. No. 2:14-02111

ALBRIGHT, ET AL. V. ABBVIE INC., ET AL., C.A. No. 2:14-02112

HARRIS, ET AL. V. ABBVIE INC, ET AL., C.A. No. 2:14-02113

Judge Ellen Segal Huvelle look no part in the decision of this matter.

1 . The motions for centralization originally included two Northern District of Illinois actions (Mecikalski and Reid) that were later remanded to state court. Additionally, in their initial motion, the Northern District of Illinois plaintiffs sought centralization of An-drogel actions; these plaintiffs later changed their request to include all testosterone replacement therapy cases in the MDL. Further, the Panel has been notified of 81 potentially related actions filed in various districts. These and any other related actions are potential tag-along actions. See Panel Rules 1.1(h), 7.1 and 7.2.